IBKS No2 SPAC

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. Its IMD offerings cover gastritis, antidepressant, anorectic, and antibiotic indications, while its generic drugs target cardiovascular, urology, pain, anti-infection, gastric, diabetes, central nervous system, respiratory, transplantation, and other areas. The company also develops new molecular entity pipeline products for dry eye disease and markets products such as Cabalin CR extended-release tablets, Jample Ibufen syrup, Gisoren tablets, and Genstring Troki. Founded in 2002, GL Pharm Tech Corp. is headquartered in Seongnam-si, South Korea.